Drug updated on 4/16/2024
| Dosage Form | Nasal spray (intranasal; 10 mg) |
| Drug Class | Calcitonin gene-related peptide receptor antagonists |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated for the acute treatment of migraine with or without aura in adults.
Summary
- Zavegepant (Zavzpret) is indicated for the acute treatment of migraine with or without aura in adults, showing promising efficacy and tolerability as an abortive treatment for episodic migraine.
- Four systematic reviews/meta-analyses were analyzed to gather information on the safety and effectiveness of this drug compared to others used for similar indications.
- Compared to lasmiditan, rimegepant, and ubrogepant, Zavegepant may be less effective at achieving immediate pain relief within 2 hours or sustaining pain relief over 24 hours. However, it appears that Zavegepant has a better safety profile than lasmiditan, which exhibits the highest risk of adverse events.
- Among intranasal therapies, while butorphanol excels at 1-hour pain freedom and zolmitriptan displays high efficacy for pain freedom at two hours post-administration, Zavegepant nasal spray stands out due to its lower risk of adverse events, indicating a superior safety profile among these agents.
- A study suggests that Zavegepant is more effective than placebo in achieving both short-term (pain freedom within two hours) and long-term outcomes (sustained pain freedom between 2 to 48 hours), although its effect on preventing relapse remains inconclusive.
- The studies indicate that despite some alternatives like lasmiditan showing higher immediate efficacy rates, the overall balance between effectiveness against migraines - especially with rapid onset when administered nasally - coupled with fewer side effects, makes Zavzpret a compelling choice, particularly among adult patients who prioritize convenience alongside fewer side effects.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Zavzpret (zavegepant) Prescribing Information. | 2023 | Pfizer Laboratories, Div Pfizer Inc., New York, NY |
Systematic Reviews / Meta-Analyses
| Document Title | Year | Source |
|---|---|---|
| Comparison of effectiveness and safety of lasmiditan and CGRP-antagonists for the acute treatment of migraine in adults: systematic review and network meta-analysis of randomised trials. | 2024 | The Journal of Headache and Pain |
| Efficacy and safety of intranasal agents for the acute treatment of migraine: a systematic review and network meta-analysis. | 2023 | The Journal of Headache and Pain |
| Safety and efficacy of zavegepant in treating migraine: a systematic review. | 2023 | Cureus |
| Zavegepant nasal spray for the acute treatment of migraine: a meta analysis. | 2023 | Medicine |